Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
In clinical trials, treatment proved more effective than other therapies evaluated
India has the second-largest number of adults with diabetes globally, after China
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Subscribe To Our Newsletter & Stay Updated
